SUPN Stock Recent News
SUPN LATEST HEADLINES
NEW YORK, NY / ACCESS Newswire / March 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
ROCKVILLE, Md., March 04, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences:
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / March 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / February 28, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
ROCKVILLE, Md., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A. Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 11:10 a.m. ET in Boston, Mass.
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
NEW YORK, NY / ACCESS Newswire / February 26, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:SUPN) concerning possible violations of federal securities laws. On February 19, 2025, The company announced that its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint, showing no significant improvement over placebo.
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals, Inc. (SUPN) Q4 2024 Earnings Call Transcript